Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases
Fridkis-Hareli, Masha, Storek, Michael, Mazsaroff, Istvan, Risitano, Antonio M., Lundberg, Ante S., Horvath, Christopher J., Holers, V. Michael
Published in Blood (27.10.2011)
Published in Blood (27.10.2011)
Get full text
Journal Article
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers
Gilbert, James C, DeFeo-Fraulini, Tia, Hutabarat, Renta M, Horvath, Christopher J, Merlino, Patricia G, Marsh, H Nicholas, Healy, Judith M, Boufakhreddine, Sleiman, Holohan, Thomas V, Schaub, Robert G
Published in Circulation (New York, N.Y.) (04.12.2007)
Published in Circulation (New York, N.Y.) (04.12.2007)
Get full text
Journal Article
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Friedman, Kevin M, Garrett, Tracy E, Evans, John W, Horton, Holly M, Latimer, Howard J, Seidel, Stacie L, Horvath, Christopher J, Morgan, Richard A
Published in Human gene therapy (01.05.2018)
Published in Human gene therapy (01.05.2018)
Get more information
Journal Article
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment
RISITANO, Antonio M, NOTARO, Rosario, LUZZATTO, Lucio, MICHAEL HOLERS, V, PASCARIELLO, Caterina, SICA, Michela, VECCHIO, Luigi Del, HORVATH, Christopher J, FRIDKIS-HARELI, Masha, SELLERI, Carmine, LINDORFER, Margaret A, TAYLOR, Ronald P
Published in Blood (28.06.2012)
Published in Blood (28.06.2012)
Get full text
Journal Article
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization
Risitano, Antonio M., Notaro, Rosario, Pascariello, Caterina, Sica, Michela, del Vecchio, Luigi, Horvath, Christopher J., Fridkis-Hareli, Masha, Selleri, Carmine, Lindorfer, Margaret A., Taylor, Ronald P., Luzzatto, Lucio, Holers, V. Michael
Published in Blood (28.06.2012)
Published in Blood (28.06.2012)
Get full text
Journal Article
Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes
Rose, Eileen, Moore, Stephen J., Cai, Allen, He, Alina, Huck, Ian, Razo, Jen, Wong, Laurie, Chan, Joanne, Horvath, Christopher J., Liu, John, Panicker, Sandip
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Pre-Clinical Characterization of VGA039, an Anti-Protein S Monoclonal Antibody Being Developed As a Universal Hemostatic Agent for Various Bleeding Disorders
Leong, Lilley, Byun, Tony, Kim, Benjamin, Huck, Ian, Silva, Abel, Chan, Joanne, Cho, Young, Liu, John, Horvath, Christopher J., Moore, Stephen J., Panicker, Sandip
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control
Rottman, James B, Ganley, Kenneth, Daly, Brenna, Horton, Holly M., Friedman, Kevin M., Perkins, Molly, Grande, Shannon, Rhodes, Claire J, Morgan, Richard A., Horvath, Christopher J.
Published in Blood (08.12.2017)
Published in Blood (08.12.2017)
Get full text
Journal Article
A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances
Chekmasova, Alena A., Horton, Holly M., Garrett, Tracy E., Evans, John W., Griecci, Johanna, Hamel, Amanda, Latimer, Howard J., Seidel, Stacie L., Ryu, Byoung Y., Kuczewski, Michael, Horvath, Christopher J., Friedman, Kevin M., Morgan, Richard A.
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells
Perkins, Molly R., Grande, Shannon, Hamel, Amanda, Horton, Holly M., Garrett, Tracy E., Miller, Sara M., Latimer, Howard J., Horvath, Christopher J., Kuczewski, Michael, Friedman, Kevin M., Morgan, Richard A.
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis
Fridkis-Hareli, Masha, Storek, Michael, Risitano, Antonio M., Lundberg, Ante S., Horvath, Christopher J, Holers, V. Michael
Published in Blood (19.11.2010)
Published in Blood (19.11.2010)
Get full text
Journal Article
C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes
Risitano, Antonio M., Pascariello, Caterina, Del Vecchio, Luigi, Horvath, Christopher J, Fridkis-Hareli, Masha, Holers, V. Michael, Lindorfer, Margaret A, Taylor, Ronald P
Published in Blood (19.11.2010)
Published in Blood (19.11.2010)
Get full text
Journal Article
TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity
Holers, V. Michael, Mazsaroff, Istvan, Akana, Hillary, Smith, Christopher G., Emlen, J. Woodruff, Marians, Russell C., Horvath, Christopher J.
Published in Blood (20.11.2009)
Published in Blood (20.11.2009)
Get full text
Journal Article
A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity
Garrett, Tracy E, Chekmasova, Alena A, Evans, John W, Seidel, Stacie L, Horton, Holly M, Latimer, Howard J, Griecci, Johanna A, Horvath, Christopher J, Ryu, Byoung Y, Friedman, Kevin M, Morgan, Richard A
Published in Journal for immunotherapy of cancer (04.11.2015)
Published in Journal for immunotherapy of cancer (04.11.2015)
Get full text
Journal Article
The human complement receptor type 2/factor H fusion protein TT30, an alternative pathway specific complement inhibitor, prevents hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria by membrane-targeting of factor H activity
Risitano, Antonio M., Pascariello, Caterina, Selleri, Carmine, Del Vecchio, Luigi, Sica, Michela, Fridkis-Hareli, Masha, Mazsaroff, Istvan, Horvath, Christopher J., Holers, V. Michael
Published in Molecular immunology (01.08.2010)
Published in Molecular immunology (01.08.2010)
Get full text
Journal Article
Abstract 3218: Pharmacokinetics, Pharmacodynamics, and Safety of an Anti-von Willebrand Factor Therapeutic Aptamer, ARC1779, in Healthy Volunteers
Gilbert, James C, DeFeo-Fraulini, Tia, Hutabarat, Renta M, Horvath, Christopher J, Merlino, Patricia G, Marsh, H N, Healy, Judy M, Fahkreddine, Sleiman B, Holohan, Thomas V, Schaub, Robert
Published in Circulation (New York, N.Y.) (16.10.2007)
Published in Circulation (New York, N.Y.) (16.10.2007)
Get full text
Journal Article